LTR Pharma Co-Founds, Takes Up 33% Stake in Omega-3 Products Firm, Shares Rise Above 3%

MT Newswires Live

Sep 22, 2025

LTR Pharma (ASX:LTP) acquired a 33% equity stake in LevOmega, which was co-founded by Levur, Green Blue Health, and the firm, with no upfront capital required, according to a Monday Australian bourse filing.

LevOmega, which is focused on developing nature-identical omega-3 products, entered into a research and development services and licensing agreement with Levur, under which it will license its proprietary advanced biotechnology platform to LevOmega.

LTR's shares jumped over 3% in recent trading on Monday.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/news/2569027296"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2569027296\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2569027296?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-09-22 10:36","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2569027296","market":"fut","top_or_hot":-1,"title":"LTR Pharma Co-Founds, Takes Up 33% Stake in Omega-3 Products Firm, Shares Rise Above 3%","media":"MT Newswires Live","content":"<html><body><p> LTR Pharma (ASX:LTP) acquired a 33% equity stake in LevOmega, which was co-founded by Levur, Green Blue Health, and the firm, with no upfront capital required, according to a Monday Australian bourse filing.</p><p>LevOmega, which is focused on developing nature-identical omega-3 products, entered into a research and development services and licensing agreement with Levur, under which it will license its proprietary advanced biotechnology platform to LevOmega.</p><p>LTR's shares jumped over 3% in recent trading on Monday.</p></body></html>","source":"mtnewswires_news","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>LTR Pharma Co-Founds, Takes Up 33% Stake in Omega-3 Products Firm, Shares Rise Above 3%</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nLTR Pharma Co-Founds, Takes Up 33% Stake in Omega-3 Products Firm, Shares Rise Above 3%\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1092851196\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">MT Newswires Live </p>\n<p class=\"h-time\">2025-09-22 10:36</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html><body><p> LTR Pharma (ASX:LTP) acquired a 33% equity stake in LevOmega, which was co-founded by Levur, Green Blue Health, and the firm, with no upfront capital required, according to a Monday Australian bourse filing.</p><p>LevOmega, which is focused on developing nature-identical omega-3 products, entered into a research and development services and licensing agreement with Levur, under which it will license its proprietary advanced biotechnology platform to LevOmega.</p><p>LTR's shares jumped over 3% in recent trading on Monday.</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"LTP.AU","symbol_name":"LTR PHARMA LTD","start_time":0,"source_url":"https://www.mtnewswires.com/","article_id":"2569027296","we_media_id":"1092851196","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2569027296","pubTimestamp":1758508609,"columns":[],"sourceInfo":{"source_id":"mtnewswires_news","name":"MT Newswires"},"weMediaInfo":{"media_name":"MT Newswires Live","introduction":"The most recognized names in North America, Europe and Asia rely on MT Newswires to power their applications. Better news, better service, better price.","home_visible":1,"id":"1092851196","head_image":"https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e"},"summary":"LTR Pharma  acquired a 33% equity stake in LevOmega, which was co-founded by Levur, Green Blue Health, and the firm, with no upfront capital required, according to a Monday Australian bourse filing.LevOmega, which is focused on developing nature-identical omega-3 products, entered into a research and development services and licensing agreement with Levur, under which it will license its proprietary advanced biotechnology platform to LevOmega.LTR's shares jumped over 3% in recent trading on Monday.","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"LTP.AU":"LTR PHARMA LTD","BK7096":"制药"},"translate_title":"LTR Pharma联合创始人，持有Omega-3产品公司33%的股份，股价升至3%以上","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"LTP.AU":1},"content_text":"LTR Pharma (ASX:LTP) acquired a 33% equity stake in LevOmega, which was co-founded by Levur, Green Blue Health, and the firm, with no upfront capital required, according to a Monday Australian bourse filing.LevOmega, which is focused on developing nature-identical omega-3 products, entered into a research and development services and licensing agreement with Levur, under which it will license its proprietary advanced biotechnology platform to LevOmega.LTR's shares jumped over 3% in recent trading on Monday.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"corporation","news_rank":0,"symbols":[],"gpt_button":1,"need_auth":false,"code":"91000000","status":"200"}}}